Expert Advises Patients with CLL on Three Things They Should Be Aware of To Maximize the Benefit of Upfront Treatment

Video

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.

Patients with chronic lymphocytic leukemia must remain observant and report any side effects, especially if they are serious, to ensure that they get the most out of their upfront treatment, according to Dr. Mazyar Shadman.

In an interview with CURE®, Shadman, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Center, discussed ways that patients can play a role in ensuring that they are able to reap the benefits of treatment.

Transcription:

First of all, they need to be well educated about the potential side effects of this treatment. So, some side effects are more serious. And they need to know that if that happens, they need to call the physician or the team as soon as possible. For example, if you're on a Bruton tyrosine kinase inhibitor, and you know (there’s) bleeding, you need to notify your physician. So, just be aware of side effects and know that some of them are more urgent and others are not, but make sure you are in communication with your team.

These days, we have a lot of options we can (use), using BTK inhibitors as an example, we have now next generation BTK inhibitors that are basically better tolerated so we can always switch treatment to one of the novel ones or maybe even change the class to a completely different type of therapy.

Number one would be knowing the side effects. Number two (is) just knowing what to expect, again, a lot of times, it's not uncommon for patients who; we do get a lot of the second opinions and consults. And they just didn't know that this treatment, for example, is not supposed to be stopped. They're like, ‘Oh, I'm taking a nap for a year.’ So, give a realistic expectation to the patient on what to expect from a drug like ibrutinib or acalabrutinib … or duvelisib if you're in the relapsed setting. Also, with venetoclax, just give the realistic expectation (that) yes, we do give the treatment for one year, but I can't promise that at the end of one year, if I stop, you'll be in remission for years, right? It depends on how good (you respond) to the treatment. So, number two would be giving realistic expectations (and) number three … goes back to this principle of a doctor-patient relationship and we have to come up with a plan that both are comfortable with. Some patients just feel safer to be watched a little bit more closely and some don't.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE